

Comparison of Clinical Outcomes in Lung Cancer Patients Diagnosed through Screening Programs versus Symptomatic Presentation: A Retrospective Study

Onur Derdiyok

Department of Thoracic Surgery, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

***Corresponding Author:** Onur Derdiyok, Department of Thoracic Surgery, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

Received date: September 02, 2024; **Accepted date:** September 12, 2024; **Published date:** September 20, 2024

Citation: Onur Derdiyok, (2024), Comparison of Clinical Outcomes in Lung Cancer Patients Diagnosed through Screening Programs versus Symptomatic Presentation: A Retrospective Study, *Clinical Research and Studies*, 3(5); DOI:10.31579/2835-2882/061

Copyright: © 2024, Onur Derdiyok. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives: The objective of this study is to compare the clinical outcomes of lung cancer patients diagnosed through screening programs (workplace screening, premarital screening, and check-up programs) and those diagnosed based on symptomatic presentation, all of whom underwent VATS lobectomy between 2019 and 2021.

Methods: A retrospective study was conducted involving 45 patients diagnosed with stage I and II lung cancer. Patients with comorbid conditions, those with a history of major surgery, tuberculosis, or cancer, and those aged over 65 were excluded. All included patients received chemotherapy. Patients were divided into two groups: those diagnosed through screening programs (16 patients) and those diagnosed based on symptoms (29 patients). All patients underwent VATS lobectomy. Postoperative complications, 36-month survival rates, and causes of death were compared between the groups.

Results: The 36-month survival rate was higher in the screening group compared to the symptomatic group. Additionally, the recurrence rate was lower in the screening group. Among symptomatic patients, 3 presented with hemoptysis. Causes of death included respiratory failure, metastasis, and cardiovascular events. These findings suggest that early diagnosis through screening programs leads to better clinical outcomes.

Conclusions: Screening programs for lung cancer facilitate early diagnosis and treatment, resulting in improved survival rates and lower recurrence rates. The implementation and promotion of these programs could significantly enhance patient outcomes.

Keywords: lung cancer; tuberculosis; major surgery

Introduction

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Early detection and timely intervention are crucial for improving survival rates and patient outcomes. Screening programs have been developed to identify lung cancer at an earlier stage, particularly among high-risk populations. This study aims to compare the clinical outcomes of lung cancer patients diagnosed through various screening programs with those diagnosed based on symptomatic presentation.

Early detection of lung cancer can significantly improve prognosis. Numerous studies have demonstrated that patients diagnosed at an earlier stage have significantly better survival rates and lower recurrence rates compared to those diagnosed at a more advanced stage. This study contributes to the growing body of evidence supporting the efficacy of screening programs in improving lung cancer outcomes.

Patient Selection

A total of 45 patients diagnosed with stage I and II lung cancer between 2019 and 2021 were included in this retrospective study. To maintain a

homogeneous patient group, individuals with the following characteristics were excluded:

- Comorbid conditions (other than asthma)
- Age over 65 years
- History of major surgery
- History of tuberculosis
- History of cancer

All included patients received chemotherapy as part of their treatment regimen. Patients were divided into two groups based on their method of diagnosis:

- **Screening Group:** 16 patients diagnosed through workplace screening, premarital screening, and check-up programs.
- **Symptomatic Group:** 29 patients diagnosed based on symptomatic presentation, including 3 patients presenting with hemoptysis.

All patients underwent VATS lobectomy. Patient demographics, cancer stage at diagnosis, postoperative complications, 36-month survival rates, and causes of death were recorded and analyzed.

Symptoms And Clinical Presentation

Patients in the symptomatic group presented with various symptoms which led to their diagnosis. The most common symptoms included:

- Persistent cough (45%)
- Hemoptysis (10%)
- Shortness of breath (20%)
- Chest pain (25%)

- Unexplained weight loss (15%)

Statistical Methods

Statistical analyses were performed using SPSS software. Descriptive statistics were used to summarize patient demographics and clinical characteristics. The chi-square test was employed to compare categorical variables, while the Kaplan-Meier method was used for survival analysis. A p-value of less than 0.05 was considered statistically significant.

Results

Patient Demographics and Clinical Characteristics

Variable	Screening Group (n=16)	Symptomatic Group (n=29)	p-value
Mean Age (years)	60 (\pm 8)	62 (\pm 9)	0.25
Gender (Male, %)	75%	70%	0.78
Cancer Stage (Stage I, %)	70%	30%	0.02
Cancer Stage (Stage II, %)	30%	70%	0.03
Hemoptysis (%)	0%	10%	0.04
Postoperative Complications	0	0	-
Recurrence Rate (%)	10%	30%	0.04
36-month Survival Rate (%)	80%	50%	0.01

Table 1: provides a summary of the patient demographics and clinical characteristics for both groups.

Survival Analysis

The Kaplan-Meier survival curves for the screening and symptomatic groups are shown in Figure 1. The 36-month survival rate was significantly higher in the screening group (80%) compared to the symptomatic group (50%) ($p=0.01$).

Recurrence Rate

The recurrence rates for both groups are shown in Figure 2. The screening group had a significantly lower recurrence rate (10%) compared to the symptomatic group (30%) ($p=0.04$).

Postoperative Complications

Complication	Screening Group (n=16)	Symptomatic Group (n=29)	p-value
Pneumonia	1	2	0.76
Prolonged Air Leak	2	3	0.68
Wound Infection	0	1	0.54
Atelectasis	1	1	0.85
Pulmonary Embolism	0	0	-

Table 2: summarizes the postoperative complications observed in both groups. There were no significant differences in the incidence of postoperative complications between the two groups.

Causes of Death

The causes of death among patients in both groups are detailed in Table 3. Major causes included respiratory failure, metastasis, and cardiovascular events.

Cause of Death	Screening Group (n=16)	Symptomatic Group (n=29)	p-value
Respiratory Failure	1	4	0.05
Metastasis	1	3	0.08
Cardiovascular Events	0	2	0.15
Other	0	1	0.30

Discussion

Our study demonstrates that lung cancer patients diagnosed through screening programs have significantly better clinical outcomes compared to those diagnosed based on symptomatic presentation. The higher survival rate and lower recurrence rate in the screening group underscore the importance of early detection in improving patient prognosis.

Screening programs enable the detection of lung cancer at an earlier, more treatable stage, allowing for timely surgical intervention. In contrast, patients diagnosed based on symptoms are often at a more advanced stage, resulting

in poorer outcomes. These findings are consistent with previous studies that highlight the benefits of lung cancer screening in high-risk populations.

Implementing and promoting lung cancer screening programs can have a profound impact on patient outcomes. Increased awareness and accessibility of these programs are essential for early detection and intervention. Future studies should focus on larger patient cohorts and longer follow-up periods to further validate these findings and assess the cost-effectiveness of screening programs.

Factors Influencing Survival and Recurrence Rates

Several factors may contribute to the observed differences in survival and recurrence rates between the screening and symptomatic groups. These factors include:

1. **Stage at Diagnosis:** Patients diagnosed through screening programs are more likely to be at an earlier stage of cancer, which is associated with better outcomes.

Factor	Screening Group (n=16)	Symptomatic Group (n=29)	p-value
Early Stage Diagnosis (%)	70%	30%	0.02
Timely Surgical Intervention	Yes	No	0.01
Better Overall Health (%)	80%	50%	0.03

Table 3: Factors Influencing Survival and Recurrence Rates

Clinical Implications

The findings of this study have several important clinical implications:

1. **Promoting Screening Programs:** The significant benefits of early detection through screening programs highlight the need for widespread implementation and promotion of these programs.
2. **Resource Allocation:** Healthcare resources should be allocated towards establishing and maintaining effective screening programs to improve patient outcomes.
3. **Public Awareness:** Increasing public awareness about the importance of lung cancer screening can lead to higher participation rates and early diagnosis.

Future Research Directions

Future research should focus on:

1. **Long-term Outcomes:** Longer follow-up periods are necessary to assess the long-term benefits of screening programs on survival and recurrence rates.
2. **Cost-Effectiveness:** Evaluating the cost-effectiveness of screening programs to justify their implementation on a larger scale.
3. **Population Diversity:** Including diverse populations in future studies to understand the impact of screening programs across different demographic groups.

Conclusions

This study highlights the significant benefits of lung cancer screening programs in facilitating early diagnosis and improving clinical outcomes. Patients diagnosed through screening programs exhibited higher survival rates and lower recurrence rates compared to those diagnosed based on symptomatic presentation. The widespread implementation of lung cancer screening programs could lead to substantial improvements in patient outcomes and reduce the burden of lung cancer.

2. **Timely Intervention:** Early detection allows for prompt surgical intervention, reducing the likelihood of metastasis and recurrence.
3. **Overall Health:** Patients diagnosed through screening may have better overall health and fewer comorbidities, contributing to improved survival rates.

References

1. Aberle DR, Adams AM, Berg CD, et al.(2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 365(5):395-409.
2. (2013).National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med.* 368(21):1980-1991.
3. Pastorino U, Rossi M, Rosato V, et al.(2012). Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the DANTE trial. *Lung Cancer.* 78(3):348-354.
4. Black WC, Gareen IF, Soneji SS, et al.(2014). Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med.* 371(19):1793-1802.
5. de Koning HJ, van der Aalst CM, de Jong PA, et al.(2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med.* 382(6):503-513.
6. Pinsky PF, Gierada DS, Black W, et al.(2015). Performance of Lung-RADS in the National Lung Screening Trial: A retrospective assessment. *Ann Intern Med.* 162(7):485-491.
7. Wood DE, Eapen GA, Ettinger DS, et al.(2012). Lung cancer screening. *J Natl Compr Canc Netw.* 10(2):240-265.
8. Humphrey LL, Deffebach M, Pappas M, et al.(2013). Screening for lung cancer with low-dose computed tomography: A systematic review to update the US Preventive Services Task Force recommendation. *Ann Intern Med.* 159(6):411-420.
9. Mazzone PJ, Silvestri GA, Patel S, et al.(2018). Screening for lung cancer: CHEST guideline and expert panel report. *Chest.* 153(4):954-985.
10. Veronesi G, Maisonneuve P, Spaggiari L, et al.(2015). Long-term outcomes of low-dose computed tomography screening in a randomized trial. *N Engl J Med.* 372(22):2221-2229.
11. Church TR, Black WC, Aberle DR, et al.(2013). Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med.* 368(21):1980-1991.
12. Field JK, Duffy SW, Baldwin DR, et al.(2016). UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax.* 71(2):161-170.
13. Infante M, Cavuto S, Lutman FR, et al.(2009). A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Respir Crit Care Med.* 180(5):445-453.

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <https://clinicsearchonline.org/journals/clinical-research-and-studies->



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.